TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05156320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apitegromab
Description: Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 will be administered every 4 weeks by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apitegromab
Description: Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 will be administered every 4 weeks by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apitegromab
Description: Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 will be administered every 4 weeks by intravenous (IV) infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered every 4 weeks by intravenous (IV) infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered every 4 weeks by intravenous (IV) infusion.
Study: NCT05781607

Intervention type: COMBINATION_PRODUCT
Intervention: Patient education combined with drug therapy
Description: Receive a health education by a specialist therapist, including explaining the anatomy and function of TMJ; Explain the etiology, prognosis, treatment plan and prognosis of TMD; Correct the patients' daily oral habits, such as unilateral chewing, habitual clenching, eating too much hard food, etc; Instruct the patient to understand the rest position of the temporomandibular joint and correct the bad posture of the neck and shoulder. At the same time, corresponding medication should be given, and NSAIDS should be taken orally or externally for patients with pain.

Intervention type: COMBINATION_PRODUCT
Intervention: Individualized comprehensive physical therapy
Description: Physical factor therapy and/or manual therapy
Study: NCT05945914

Intervention type: PROCEDURE
Intervention: Oncoplastic Entirely Robot-Assisted Approach (OPERA)
Description: Robotic-assisted surgery in both mastectomy and free DIEP flap harvest, so-called Oncoplastic Entirely Robot-Assisted Approach (OPERA).
Study: NCT05759650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Execution of different motor tasks typical of daily life and work
Description: Patients with obesity will carry out different motor tasks typical of daily life and work and, using optoelectronic systems based on passive markers, force platforms and electromyographic systems, kinematic and kinetic parameters of movement will be recorded and analysed for the implementation of an integrated protocol for the clinical evaluation of subjects with obesity.
Study: NCT05151432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Ultrasound
Description: Active US therapy will be administered using a device 4cm², 1- MHz US with a sound-head area of effective 4cm, radiating area of 3.5 to a beam non-uniformity ratio of cm². 5:1, and a therapeutic dose of approximately 112.5J/ That is, the pulsed US will be delivered for 9.5 minutes with a peak intensity of 1W/cm² at a 20% duty cycle, to achieve a spatial-temporal average intensity of 0.2W

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Ultrasound
Description: Active US therapy will be administered using a device 4cm², 1- MHz US with a sound-head area of effective 4cm, radiating area of 3.5 to a beam non-uniformity ratio of cm². 5:1, and a therapeutic dose of approximately 112.5J/ That is, the pulsed US will be delivered for 9.5 minutes with a peak intensity of 1W/cm² at a 20% duty cycle, to achieve a spatial-temporal average intensity of 0.2W

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic field
Description: The patient's knee will be placed between 2 plates coil applicator generating a magnetic field intensity of 1.5 mT and a frequency of 75Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic field
Description: The patient's knee will be placed between 2 plates coil applicator generating a magnetic field intensity of 1.5 mT and a frequency of 75Hz.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercise program
Description: Stretching exercises, Isometric quadriceps exercise, Straight leg raising (SLR) exercise, Isometric hip adduction exercise, Hip abductor strengthening, Hip extensor strengthening, Hip external rotator strengthening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercise program
Description: Stretching exercises, Isometric quadriceps exercise, Straight leg raising (SLR) exercise, Isometric hip adduction exercise, Hip abductor strengthening, Hip extensor strengthening, Hip external rotator strengthening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercise program
Description: Stretching exercises, Isometric quadriceps exercise, Straight leg raising (SLR) exercise, Isometric hip adduction exercise, Hip abductor strengthening, Hip extensor strengthening, Hip external rotator strengthening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercise program
Description: Stretching exercises, Isometric quadriceps exercise, Straight leg raising (SLR) exercise, Isometric hip adduction exercise, Hip abductor strengthening, Hip extensor strengthening, Hip external rotator strengthening

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Pulsed US & Electromagnetic field
Description: The patients will receive Sham Pulsed US \& Electromagnetic field.
Study: NCT04899440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water Flosser
Description: A pressurized stream of water to reduce gingivitis and remove adherent plaque

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No Oral Irrigator Control
Study: NCT01320761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101-BA-free
Description: ATX-101-BA-free

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101-BA-free
Description: ATX-101-BA-free

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101-BA-free
Description: ATX-101-BA-free

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101-BA-free
Description: ATX-101-BA-free

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101-BA
Description: ATX-101-BA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101-BA
Description: ATX-101-BA
Study: NCT06415994

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants will answer questionnaires on their medical history, pregnancy, substance use, and after birth: their child's development

Intervention type: OTHER
Intervention: Blood and Placental Samples
Description: At each MRI visit a blood sample will be collected for substances, DNA, RNA, epigenetics, and placental biomarkers.~At delivery: A sample of placenta will be collected for RNA, DNA, and epigenetic analysis.

Intervention type: OTHER
Intervention: Blood and Placental Samples
Description: At each MRI visit a blood sample will be collected for substances, DNA, RNA, epigenetics, and placental biomarkers.~At delivery: A sample of placenta will be collected for RNA, DNA, and epigenetic analysis.
Study: NCT05035563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention. Early and integral communication strategy (EICS)
Description: This intervention will be implemented in patients since they are hospitalized in the ICU where is expected:~* Facilitate contact and communication between patients, families and the health team.~* Respond to the communication needs of family members.~* Reduce equipment overload and facilitate communication with families and patients, providing tools and timely support.~* Build a positive and trusting relationship of relatives and patients with health teams.~The intervention considers the following actions:~1. - Training in communication to the health team~2. - Written material~3. - Family website~4. - Standardized and daily telephone information~5. - Health Team Support Strategy~6. - Weekly multidisciplinary virtual meeting with the family~7. - ICU diaries for family members
Study: NCT01320761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101-BA
Description: ATX-101-BA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101-BA
Description: ATX-101-BA
Study: NCT05030415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab Auto-Injector
Description: 160 mg week 0 followed by 80 mg every two weeks
Study: NCT05085704

Intervention type: DEVICE
Intervention: Magnetic resonance imaging
Description: Medical imaging technique used in radiology to form pictures of the anatomy.

Intervention type: DEVICE
Intervention: Magnetic resonance imaging
Description: Medical imaging technique used in radiology to form pictures of the anatomy.
Study: NCT05401695

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA330 hemoadsorption technique
Description: Hemoadsorption (HA) treatment An HA330 disposable hemoperfusion cartridge (HA330; Jafron, Zhuhai City, China) was used with a continuous renal replacement therapy (CRRT) machine (Aquarius® or Primaflex®) in the intervention group. We will select a blood circuit for each machine according to the patient's body weight. Vascular access will be established with ultrasound-guided insertion of a double-lumen venous catheter into the right internal jugular or femoral vein. HA will be performed for a maximum of 4 hours, and the second session will be started approximately 24 hours after the end of the first session. The blood flow rate will be started low and be gradually increased while monitoring real-time blood pressure and vital signs with an arterial-line monitor. After the end of the HA session, CRRT will be continued if required.
Study: NCT06481228

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: CAR-T cells as consolidation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: BCL2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olverembatinib
Description: TKI
Study: NCT06261736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Description: These participants will be given a single dose of an oral antibiotic prior to the procedure.

Intervention type: OTHER
Group type: OTHER
Intervention: No antibiotics
Description: These participants will not be given an antibiotic prior to the procedure.
Study: NCT05581082

Intervention type: OTHER
Intervention: Pragmatic, exploratory study of Precision Medicine
Description: This pragmatic, exploratory study consists of individuals with frailty who are referred from routine care to a physical therapy-based strengthening intervention. This specific study will collect ancillary measures to evaluate our outcomes. The study staff will not be conducting any interventions themselves - the physical therapy program is as per usual care.
Study: NCT05087927

Intervention type: BEHAVIORAL
Intervention: Gain framing plus demographically targeted photos
Description: Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races.

Intervention type: BEHAVIORAL
Intervention: Gain framing plus demographically targeted photos
Description: Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races.

Intervention type: BEHAVIORAL
Intervention: Loss framing plus demographically targeted photos
Description: Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races.

Intervention type: BEHAVIORAL
Intervention: Loss framing plus demographically targeted photos
Description: Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races.

Intervention type: BEHAVIORAL
Intervention: Gain framing plus not demographically targeted photos
Description: Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of an African American woman.

Intervention type: BEHAVIORAL
Intervention: Gain framing plus not demographically targeted photos
Description: Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of an African American woman.

Intervention type: BEHAVIORAL
Intervention: Loss framing plus not demographically targeted photos
Description: Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of an African American woman.

Intervention type: BEHAVIORAL
Intervention: Loss framing plus not demographically targeted photos
Description: Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of an African American woman.
Study: NCT06067685

Intervention type: OTHER
Intervention: Observation
Description: Prospective Observation only. Will record serum triglyceride, fingerstick blood triglyceride measurements, cord c-peptide, and neonatal body fat composition measurements in the first 6 months.
Study: NCT05522244

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: extended CTA
Description: Extending the standard CTA 6 cm below the carina.
Study: NCT05988294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: One-hour Pilates exercise program was given by a certified trainer to patients three times per week for 12 weeks. The exercise program followed the basic principles of the Pilates method. Our protocol comprised the following components of Pilates-based exercises: strength and stabilization, flexibility and range of motion, proper body alignment, balance, coordination, and body awareness. Resistance bands and 26 cm Pilates balls were used as supportive equipment. The exercise sections consisted of 5 minutes breathing, 10 minutes warm-up, 35 minutes conditioning phase and 10 minutes cool-down.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy exercise program
Description: Diaphragmatic deep breathing exercises, bronchial hygiene techniques, assisted cough, stretching exercises and ROM exercises for both upper and lower limbs for 45 minutes, 3 days/ week for 12 weeks.
Study: NCT05470023

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OTC Toothpastes or Mouthrinses
Description: OTC Toothpastes or mouthrinses used according to standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OTC Toothpastes or Mouthrinses
Description: OTC Toothpastes or mouthrinses used according to standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OTC Toothpastes or Mouthrinses
Description: OTC Toothpastes or mouthrinses used according to standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OTC Toothpastes or Mouthrinses
Description: OTC Toothpastes or mouthrinses used according to standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OTC Toothpastes or Mouthrinses
Description: OTC Toothpastes or mouthrinses used according to standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OTC Toothpastes or Mouthrinses
Description: OTC Toothpastes or mouthrinses used according to standard of care
Study: NCT06251050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium-containing mouthwash
Description: The main ingredients of lithium-containing mouthwash are lithium carbonate and citric acid. A total of 5 concentration gradients of lithium-containing mouthwash are set, including 0.03, 0.06, 0.10, 0.15 and 0.21 mol/L. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium-containing mouthwash
Description: The main ingredients of lithium-containing mouthwash are lithium carbonate and citric acid. A total of 5 concentration gradients of lithium-containing mouthwash are set, including 0.03, 0.06, 0.10, 0.15 and 0.21 mol/L. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium-containing mouthwash
Description: The main ingredients of lithium-containing mouthwash are lithium carbonate and citric acid. A total of 5 concentration gradients of lithium-containing mouthwash are set, including 0.03, 0.06, 0.10, 0.15 and 0.21 mol/L. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium-containing mouthwash
Description: The main ingredients of lithium-containing mouthwash are lithium carbonate and citric acid. A total of 5 concentration gradients of lithium-containing mouthwash are set, including 0.03, 0.06, 0.10, 0.15 and 0.21 mol/L. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium-containing mouthwash
Description: The main ingredients of lithium-containing mouthwash are lithium carbonate and citric acid. A total of 5 concentration gradients of lithium-containing mouthwash are set, including 0.03, 0.06, 0.10, 0.15 and 0.21 mol/L. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Plcacebo mouthwash
Description: Placebo Mouthwash is mainly composed of citric acid and sodium hydroxide, transparent colorless liquid. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lithium-containing mouthwash
Description: Effective lithium salt concentrations screened in the Phase I trial is used as active interventions in this group of interventions. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
Study: NCT05988294

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional physical therapy exercise program
Description: Diaphragmatic deep breathing exercises, bronchial hygiene techniques, assisted cough, stretching exercises and ROM exercises for both upper and lower limbs for 45 minutes, 3 days/ week for 12 weeks.
Study: NCT06458192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Messaging Intervention
Description: The intervention delivers 8 weeks of daily text messaging. Messages will arrive throughout the day via SMS to prompt learning and applying cognitive and behavioral self-management strategies, representing a variety of self-management strategies and message tones. The intervention will apply reinforcement learning to select daily messaging styles to maximize user engagement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Adaptive Messaging Intervention
Description: The intervention involves 8 weeks of daily text messaging. Messages will arrive throughout the day via SMS to prompt learning and applying cognitive and behavioral self-management strategies, representing a variety of self-management strategies and message tones. Daily messaging styles will be randomly selected.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation-Only Control
Description: An active control which will deliver psychoeducational content via clickable URLs over 8 weeks.
Study: NCT05948267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine- dexmeditomidine admixure
Description: ketamine in anesthetic dose mixed with two different doses of dexmeditomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine- dexmeditomidine admixure
Description: ketamine in anesthetic dose mixed with two different doses of dexmeditomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol, Lidocaine and fentanyl
Description: Propofol (2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml
Study: NCT06541054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WARM SOCKS
Description: One hour before the operation,warm socks will be put on the experimental group,body temperature,heart rate,blood pressure,SPO2 will be measured and recorded every fifteen minutes.During the surgery,body temperature,heart rate,blood pressure,SPO2 value, drainage amount will be measured and recorded every fifteen minutes.The patient will be transferred to the postoperative care unit with warm socks and will stay on his feet in the postoperative care unit.Body temperature, heart rate,blood pressure,SPO2 values will be recorded every fifteen minutes.He will be transferred from the postoperative care unit to the clinic with socks.will stay. After transferring to the bed,body temperature,heart rate, arterial blood pressure, SPO2 will be recorded every fifteen minutes for a total of 180minutes.Chills,chills and the total drainage amount for 24hours will be recorded in the same section.
Study: NCT04914676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Subjects on this arm will prospectively receive consolidation therapy with cytarabine. Subjects will be treated with 1000 mg/m2 cytarabine intravenously every 12 hours on Days 1-3 of each consolidation cycle. Subjects will receive up to four consolidation cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: Subjects on this arm will have received consolidation therapy with cytarabine between 2/1/2017 and 2/1/2019. Subjects will have received 1000 mg/m2 cytarabine intravenously every 12 hours on days 1, 3, and 5 of each consolidation cycle and will have received up to 4 consolidation cycles.